Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1Breceptor antagonists: TASP0233278 and TASP0390325

Autor:	Michihiko Iijima, K Tokugawa, T Kuwada, Kenichi Fukumoto, Takao Yoshimizu, Yoshinori Sekiguchi, Shigeyuki Chaki, Toshiharu Shimazaki, Shinsuke Kurosu
Rok vydání:	2014
Předmět:	Pharmacology medicine.medical_specialty business.industry medicine.drug_class Antagonist Antidiuretic Hormone Receptor Antagonists Adrenocorticotropic hormone Anxiolytic Endocrinology medicine.anatomical_structure Anterior pituitary Internal medicine medicine Antidepressant business Receptor hormones hormone substitutes and hormone antagonists Behavioural despair test
Zdroj:	British Journal of Pharmacology. 171:3511-3525
ISSN:	0007-1188
DOI:	10.1111/bph.12699
Popis:	Background and Purpose Vasopressin V1B receptor antagonists may be effective for the treatment of depression and anxiety and the objective of this study was to characterize the pharmacological profiles of two newly synthesized arginine vasopressin receptor 1B (V1B receptor) antagonists, TASP0233278 and TASP0390325. Experimental Approach We investigated the in vitro profiles of TASP0233278 and TASP0390325. In addition, the effect of TASP0390325 on the increase in plasma adrenocorticotropic hormone (ACTH) levels induced by corticotropin-releasing factor (CRF)/desmopressin (dDAVP) was investigated. We also investigated the antidepressant and anxiolytic profiles of TASP0233278 and TASP0390325 in animal models. Key Results Both TASP0233278 and TASP0390325 showed a high affinity and potent antagonist activity for V1B receptors. Oral administration of TASP0390325 antagonized the increase in plasma ACTH levels induced by CRF/dDAVP in rats, indicating that TASP0390325 blocks the anterior pituitary V1B receptor in vivo. Oral administration of TASP0233278 or TASP0390325 also exerted antidepressant effects in two models of depression (a forced swimming test and an olfactory bulbectomy model). Moreover, TASP0233278 improved depressive-like behaviour induced by repeated treatment with corticosterone, a model that has been shown to be resistant to treatment with currently prescribed antidepressants. In addition to depression models, TASP0233278 or TASP0390325 exerted anxiolytic effects in several anxiety models (social interaction, elevated plus-maze, stress-induced hyperthermia, separation-induced ultrasonic vocalization and sodium lactate-induced panic-like responses in panic-prone rats). Conclusion TASP0233278 and TASP0390325 are potent and orally active V1B receptor antagonists with antidepressant and anxiolytic activities in rodents.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b8a3451fc759dbef06b93acc72b4f345 https://doi.org/10.1111/bph.12699 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.